AEGiS-GMHC: Treatment Briefs: Reports on 3TC Data

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Treatment Briefs: Reports on 3TC Data

Gay Men's Health Crisis "Treatment Issues", Vol 8, No. 10, November, 1994

A number of unconfirmed reports suggest that the combination of 3TC (also known as lamivudine) and AZT is achieving impressive antiviral effects in studies of HIV-positive patients. Results of combination AZT/3TC studies are expected to be released this month at the Second International on Drug Therapy and HIV Infection in Glasgow, Scotland. 3TC is a nucleoside analog active in the test tube against both HIV and hepatitis B (HBV). It is at present in phase II/III trials for both HIV and HBV. Resistance to 3TC occurs rapidly when the drug is used against HIV. But test tube studies suggest that resistance to 3TC makes AZT-resistant strains of HIV again susceptible to AZT. Burroughs Wellcome, the manufacturer of AZT, has purchased an option to buy the rights to 3TC for HIV disease. An expanded access program for 3TC is available for HIV-infected adults and children with CD4 counts of less than 300. Eligible individuals must have failed or be intolerant to approved anti-HIV therapies and unable to qualify for ongoing clinical trials. Physicians can call 800/248-9757 for information.

Copyright (c) 1994 - Gay Men's Health Crisis. Noncommercial reproduction encouraged. DISTRIBUTED BY GENA/aegis * 714.248.2836 * 8N1/Full Duplex * v.34.
9411
GM081007

Copyright © 1994 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .